Oric Pharmaceuticals, Inc. Common Stock

Day range

$9.60 – $13.24

Open

$13.10

Prev close

$13.17

Volume

4.1M

Market cap

$1.37B

Shares out

103.65M

P/E

—

P/S

—

P/B

3.58

P/FCF

—

ROE

-36.8%

ROA

-34.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 23, 2026

  Enozertinib demonstrated compelling intracranial activity, including: 70% confirmed intracranial ORR by investigator... 67% (10 of 15) intracranial ORR by BICR RANO-BM... and 40% (6 of 15) intracranial complete response rate by BICR RANO-BM.

• Equity compensation grantJul 30, 2026

  the Board of Directors (the "Board") of ORIC Pharmaceuticals, Inc. (the "Company") approved the ORIC Pharmaceuticals, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan (as amended, the "Inducement Plan"), in order to increase the number of shares reserved for issuance under the Inducement Plan. Subject to the adjustment provisions of the Inducement Plan, the Board reserved an additional 1,100,000 shares of the Company's common stock, or 3,350,000 shares of common stock in the aggregate, for issuance pursuant to equity awards granted under the Inducement Plan.

• Equity compensation grantJun 22, 2026

  ORIC Pharmaceuticals, Inc. (the "Company") amended and restated its 2020 Equity Incentive Plan (the "A&R 2020 Equity Incentive Plan"), effective as of June 18, 2026 upon approval by the stockholders of the Company at the Annual Meeting. The amendments to the A&R 2020 Equity Incentive Plan included (1) amending the annual "evergreen" provision to remove the annual limit of 2,656,500 shares while reducing the annual increase from 5% to 4% of the Company's outstanding shares of common stock, (2) providing that, subject to the adjustment provisions of the A&R 2020 Equity Incentive Plan, the maximum number of shares of common stock that can be issued pursuant to the exercise of incentive stock options under the plan is 10,000,000.

• Clinical trial resultsMar 31, 2026

  The Company presented a rinzimetostat (ORIC-944) program update on March 31, 2026. The Program Update covered recently announced dose optimization data from the Company's Phase 1b trial of rinzimetostat.

• Public offeringFeb 23, 2026

  On February 26, 2026, the Company filed a prospectus supplement with the SEC in connection with the offer and sale of up to $200.0 million of Shares pursuant to the Sales Agreement (the "2026 Prospectus Supplement").

Days to cover

9.8

Short interest

16.32M

Avg volume

1.66M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
  positiveGlobeNewswire Inc.· Oct 23, 2026
• ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
  positiveGlobeNewswire Inc.· Oct 23, 2026
• ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Aug 7, 2026
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
  negativeGlobeNewswire Inc.· May 12, 2026
• ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Apr 3, 2026